The AGEN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the AGEN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The AGEN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View AGEN Detailed Price Forecast - CNN Money||View AGEN Detailed Summary - Google Finance|
|View AGEN Detailed Summary - Yahoo! Finance||View AGEN Stock Research & Analysis - Zacks.com|
|View AGEN Trends & Analysis - Trade-Ideas||View AGEN Major Holders - Barrons|
|View AGEN Call Transcripts - NASDAQ||View AGEN Breaking News & Analysis - Seeking Alpha|
|View AGEN Annual Report - CompanySpotlight.com||View AGEN OTC Short Report - OTCShortReport.com|
|View AGEN Fundamentals - TradeKing||View AGEN SEC Filings - Bar Chart|
|View Historical Prices for AGEN - The WSJ||View Performance/Total Return for AGEN - Morningstar|
|View the Analyst Estimates for AGEN - MarketWatch||View the Earnings History for AGEN - CNBC|
|View the AGEN Earnings - StockMarketWatch||View AGEN Buy or Sell Recommendations - MacroAxis|
|View the AGEN Bullish Patterns - American Bulls||View AGEN Short Pain Metrics - ShortPainBot.com|
|View AGEN Stock Mentions - StockTwits||View AGEN Stock Mentions - PennyStockTweets|
|View AGEN Stock Mentions - Twitter||View AGEN Investment Forum News - Investor Hub|
|View AGEN Stock Mentions - Yahoo! Message Board||View AGEN Stock Mentions - Seeking Alpha|
|View Insider Transactions for AGEN - SECform4.com||View Insider Transactions for AGEN - Insider Cow|
|View AGEN Major Holdings Summary - CNBC||View Insider Disclosure for AGEN - OTC Markets|
|View Insider Transactions for AGEN - Yahoo! Finance||View Institutional Holdings for AGEN - NASDAQ|
|View AGEN Stock Insight & Charts - FinViz.com||View AGEN Investment Charts - StockCharts.com|
|View AGEN Stock Overview & Charts - BarChart||View AGEN User Generated Charts - Trading View|
Agenus Appoints Regulatory and Clinical Heads
Posted on Monday July 16, 2018
LEXINGTON, Mass., July 16, 2018 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with clinical stage checkpoint antibodies, a pipeline of IND ready antibodies and bispecifics, cancer vaccines, and adoptive cell therapies1, today announced the appointment of I-O drug development experts into key leadership positions. These appointments will help advance multiple clinical programs and planned BLA filings by 2020. Drs. Gupta and Wijatyk have had successful careers leading the approvals of immune therapies and chemotherapies," said Garo H. Armen, Ph.D., Chairman and CEO of Agenus. Dr. Sunil Gupta joins Agenus as Vice President of Regulatory and Pharmacovigilance. Dr. Gupta is a trained oncologist with nearly 30 years in senior leadership positions in clinical development and regulatory affairs.
Agenus to Webcast Annual Meeting of Stockholders
Posted on Wednesday June 20, 2018
LEXINGTON, Mass. , June 20, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 invites ...
National Advisory Committee on Immunization (NACI) recommends SHINGRIX for the prevention of shingles for adults aged 50 and up
Agenus Discovery Enhances Activity of Cancer Fighting Antibodies; Findings Published in Cancer Cell
Posted on Tuesday June 12, 2018
LEXINGTON, Mass., June 12, 2018 /PRNewswire/ -- A study published in Cancer Cell reports on a novel discovery made by Agenus Inc. (AGEN) that may enhance the immune activity of cancer fighting antibodies, including those targeting CTLA-4. Agenus has applied this discovery to its proprietary next generation anti-CTLA-4 antibody (AGEN1181) on track for IND filing in 2H2018. The pre-clinical study reports on a unique mechanism discovered by Agenus, that can significantly improve the biological and immunological activity of certain cancer fighting antibodies, such as those targeting CTLA-4 and TIGIT.